Skip to main content
. 2022 Oct 6;14(19):4891. doi: 10.3390/cancers14194891

Figure 5.

Figure 5

Survival analysis of rare events from the Landscape- and CDX2-targeted immunofluorescence protocols. (A) Kaplan-Meier (KM) curve showing that patients with more than the median of 2.21 Onc CK|CD45/CD31/mL found in Draw 1 by the Landscape protocol had longer progression-free survival (PFS). (B) KM curve showing two rare events with survival implications found in Draw 2 by the CDX2-targeted protocol. Patients with more than the median of 20.61 CK|CD45 cells/mL or more than the median of 11.57 Onc CK/mL had shorter PFS. (C) Rare-event kinetics between Draw 1 and Draw 2 analyzed with the CDX2-targeted protocol, ordered from longest to shortest PFS. (D) Rare-event kinetics between Draw 1 and Draw 2 analyzed with the Landscape protocol, ordered from longest to shortest PF€(E) KM curve showing that patients with a change of ≥−1.84 CK|CDX2|CD45 cells/mL from the CDX2-targeted protocol had longer PFS. (F) KM curve showing that patients with a change of ≥−9.94 Onc CK|Vim|CD45/CD31/mL from the Landscape protocol had longer PFS.